[go: up one dir, main page]

EP0537293A4 - Ligand for cd28 receptor on b cells and methods - Google Patents

Ligand for cd28 receptor on b cells and methods

Info

Publication number
EP0537293A4
EP0537293A4 EP19910914867 EP91914867A EP0537293A4 EP 0537293 A4 EP0537293 A4 EP 0537293A4 EP 19910914867 EP19910914867 EP 19910914867 EP 91914867 A EP91914867 A EP 91914867A EP 0537293 A4 EP0537293 A4 EP 0537293A4
Authority
EP
European Patent Office
Prior art keywords
ligand
receptor
cells
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910914867
Other versions
EP0537293A1 (en
Inventor
Peter S. Linsley
Jeffrey A. Ledbetter
Nitin K. Damle
William Brady
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of EP0537293A1 publication Critical patent/EP0537293A1/en
Publication of EP0537293A4 publication Critical patent/EP0537293A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP19910914867 1990-07-02 1991-07-01 Ligand for cd28 receptor on b cells and methods Withdrawn EP0537293A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54798090A 1990-07-02 1990-07-02
US547980 1990-07-02
US72210191A 1991-06-27 1991-06-27
US722101 1991-06-27

Publications (2)

Publication Number Publication Date
EP0537293A1 EP0537293A1 (en) 1993-04-21
EP0537293A4 true EP0537293A4 (en) 1993-09-08

Family

ID=27068718

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910914867 Withdrawn EP0537293A4 (en) 1990-07-02 1991-07-01 Ligand for cd28 receptor on b cells and methods

Country Status (4)

Country Link
EP (1) EP0537293A4 (en)
JP (2) JPH06508501A (en)
CA (1) CA2086325C (en)
WO (1) WO1992000092A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
EP0575537A1 (en) * 1991-03-08 1993-12-29 Cytomed, Inc. Soluble cd28 proteins and methods of treatment therewith
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ATE272708T1 (en) * 1992-04-07 2004-08-15 Univ Michigan IMMUNE REGULATION VIA THE CD28 ROUTE
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP0651797B1 (en) * 1992-07-09 2004-01-28 Chiron Corporation A method for generation of antibodies to cell surface molecules
MX9306147A (en) * 1992-10-02 1994-06-30 Bristol Myers Squibb Co PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF TUMOR CELLS.
WO1994023760A1 (en) * 1993-04-14 1994-10-27 The United States Of America As Represented By The Secretary Of The Navy Transgenic animal model for autoimmune diseases
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
DK0700430T3 (en) * 1993-06-04 2005-08-15 Us Navy Methods to selectively stimulate proliferation of T cells
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
JPH0779793A (en) * 1993-09-14 1995-03-28 Sumitomo Electric Ind Ltd Monoclonal antibody against B70 molecule
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
DE69519513T2 (en) 1994-03-08 2001-07-19 Dana-Farber Cancer Institute, Boston METHOD FOR MODULATING "T-CELL ANERGY"
USRE38313E1 (en) * 1994-05-06 2003-11-11 Institut Gustave Roussy Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6083751A (en) * 1994-11-01 2000-07-04 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells
US5576423A (en) * 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
DE69535690T2 (en) * 1994-12-02 2009-01-15 Schering Corp. Costimulatory T-cell surface antigen SLAM
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US7041634B2 (en) 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
PT892643E (en) * 1996-03-20 2002-09-30 Univ Emory METHODS FOR INHIBITING AN IMMUNITY RESPONSE BLOCKING THE GP39 / CD40 AND CTLA4 / CD28 / B7 CIRCUITS AND USES FOR THE EFFECT
GB9607711D0 (en) * 1996-04-13 1996-06-19 Univ Sheffield T-cell dependent vaccine
CA2194814A1 (en) 1997-01-10 1998-07-10 Terry L. Delovitch Stimulation of protective t cells to prevent autoimmune disease
PT1012259E (en) 1997-06-04 2009-11-06 Oxford Biomedica Ltd Tumor targeted vector
US7279168B2 (en) 1998-05-01 2007-10-09 Texas A & M University System Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
US7078512B2 (en) 1998-05-01 2006-07-18 Schering-Plough Animal Health Corporation Nucleic acid encoding feline CD86
DE19905501B4 (en) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament
PT1234031T (en) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, a novel immunoregulatory molecule
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
MXPA02012106A (en) 2000-06-06 2003-06-06 Bristol Myers Squibb Co B7-related nucleic acids and polypeptides useful for immunomodulation.
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002066059A2 (en) * 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
HUE039237T2 (en) 2004-10-06 2018-12-28 Mayo Found Medical Education & Res B7-h1 and pd-1 in treatment of renal cell carcinoma
WO2007009064A2 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
PT1912675E (en) 2005-07-25 2014-05-09 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
MX380352B (en) 2006-06-12 2025-03-12 Aptevo Res & Development Llc SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION.
US9056906B2 (en) 2006-06-14 2015-06-16 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JP2010533649A (en) 2007-07-13 2010-10-28 ザ ジョンズ ホプキンス ユニバーシティー B7-DC variant
RS51975B (en) 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. CD37 IMMUNOTHERAPEUTIC PRODUCT AND ITS COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC AGENTS
RU2014133530A (en) * 2012-01-16 2016-03-20 Эйтокс Байо Лтд. SYNTHETIC PEPTIDES FOR THE TREATMENT OF BACTERIAL INFECTIONS
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
ES2714708T3 (en) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedures for the treatment of cancer in patients with elevated levels of Bim
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
BR112018005573A2 (en) 2015-09-21 2019-01-22 Aptevo Research And Development Llc "cd3 binding polypeptides"
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research CANCER TREATMENT METHODS AND MATERIALS
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005541A1 (en) * 1988-11-23 1990-05-31 The Regents Of The University Of Michigan Immunotherapy involving cd28 stimulation
EP0440373A1 (en) * 1990-01-25 1991-08-07 Bristol-Myers Squibb Company Method of activating cytolytic activity of lymphocytes using anti-CD28 antibody
WO1992015671A1 (en) * 1991-03-08 1992-09-17 Cytomed, Inc. Soluble cd28 proteins and methods of treatment therewith

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005541A1 (en) * 1988-11-23 1990-05-31 The Regents Of The University Of Michigan Immunotherapy involving cd28 stimulation
EP0440373A1 (en) * 1990-01-25 1991-08-07 Bristol-Myers Squibb Company Method of activating cytolytic activity of lymphocytes using anti-CD28 antibody
WO1992015671A1 (en) * 1991-03-08 1992-09-17 Cytomed, Inc. Soluble cd28 proteins and methods of treatment therewith

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF IMMUNOLOGY vol. 21, May 1991, pages 1277 - 1282 NITIN K. DAMLE ET AL. 'Direct helper T-cell induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7' *
JOURNAL OF EXPERIMENTAL MEDICINE vol. 173, March 1991, pages 721 - 730 PETER S. LINSLEY ET AL. 'Binding to the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation' *
Proceedings of the National Academy of Sciences, USA, Volume 87, July 1990, LINSLEY et al., "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1", pages 5031-5035, see entire document. *
See also references of WO9200092A1 *

Also Published As

Publication number Publication date
EP0537293A1 (en) 1993-04-21
CA2086325C (en) 2010-10-05
CA2086325A1 (en) 1992-01-03
WO1992000092A1 (en) 1992-01-09
JPH06508501A (en) 1994-09-29
JP2002186486A (en) 2002-07-02

Similar Documents

Publication Publication Date Title
EP0537293A4 (en) Ligand for cd28 receptor on b cells and methods
EP0455491A3 (en) Catalysts and methods for denitrization
GB2221343B (en) Semiconductor cell for neural network and the like
US5650703B1 (en) Downward compatible agv system and methods
IL97339A0 (en) Collosion a voidance system
EP0451860A3 (en) Expert system development support system and expert system
GB2247942B (en) Cryostat
ZA891490B (en) Closed support system
EP0342647A3 (en) Method for examining sheet-like objects
EP0331412A3 (en) Connection arrangement and method for forming the same
EP0513068A4 (en) Three new non-polyglutamatable deazaaminopterins and process for preparing the same
AU7983791A (en) Weighing apparatus and a carrier for use with the apparatus
GB8807271D0 (en) Cell fusion apparatus
GB2248490B (en) Cryostat
GB9015832D0 (en) Introducing means
GB9003498D0 (en) Seat device
IL97996A0 (en) Hybrid cellular receptor
GB8804857D0 (en) Seat/carrier unit
EP0517916A4 (en) Immunosuppressant
IL117145A0 (en) B cell differentiation and proliferation factors and methods for obtaining and using the same
EP0369102A3 (en) Modulation method and arrangement for carrying out the method
AU1304892A (en) Retaining method and means
EP0416503A3 (en) Polyarylates and method for preparing the same
PL286097A1 (en) Photothermoelectric cell
IE900964L (en) Roof seat

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/62

A4 Supplementary search report drawn up and despatched

Effective date: 19930726

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960129

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060809